Skip to main content
Premium Trial:

Request an Annual Quote

Servier, Prognomix Agree to ID Targets for Diabetes, Metabolic Disease Treatments

NEW YORK (GenomeWeb News) – Les Laboratoires Servier and Prognomix today announced a deal to identify novel targets for the development of type 2 diabetes and metabolic disease treatments.

The research and development deal will use Prognomix's platform that is based on genomics and bioinformatics technologies, a database of phenotypic and genotypic data, and results from the analysis of the data. The data analysis serves as the foundation of a knowledgebase that will be used by Servier and Prognomix.

The knowledgebase results from what the partners said is the largest clinical study ever conducted on type 2 diabetes called Advance, for which Servier was the main sponsor.

As part of the deal, Servier will make a "contract signature fee payment" of an undisclosed amount. In return, the French pharma can obtain the rights to use targets resulting from the partnership.

Prognomix is a privately held personalized medicine firm based in Montreal, focused on discovering genetic signatures that may be predictive of disease and developing them for clinical use.

The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.